contact  |  people


Our Publications



The full list of publications we can be found at www.ncbi.nlm.nih.gov/pubmed/.
For more information about any publication please contact us.



2015

Philippen LE, Dirkx E, Wit JB, Burggraaf K, de Windt LJ, da Costa Martins PA. Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis? Mol Ther. 2015. doi: 10.1038/mt.2015.133.   
Grootaert MO, da Costa Martins PA, Bitsch N, Pintelon I, De Meyer GR, Martinet W, Schrijvers DM. Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neointima formation and atherogenesis. Autophagy. 2015 [Epub ahead of print]   
Azzouzi HE, Leptidis S, Doevendans PA, De Windt LJ. HypoxamiRs: regulators of cardiac hypoxia and energy metabolism. Trends Endocrinol Metab. 2015. doi: 10.1016/j.tem.2015.06.008.   
Cannon MV, Silljé HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, van Deursen J, Silva GJ, de Windt LJ, Gustafsson JĹ, van der Harst P, van Gilst WH, de Boer RA. Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med. 2015;7(9):1229-1243.   
Poels EM, da Costa Martins PA, van Empel VP. Adaptive capacity of the right ventricle: why does it fail? Am J Physiol Heart Circ Physiol. 2015;308(8):H803-813.   
Duygu B, de Windt LJ, da Costa Martins PA. Targeting microRNAs in heart failure. Trends Cardiovasc Med. 2015. doi: 10.1016/j.tcm.2015.05.008.   
Philippen LE, Dirkx E, da Costa Martins PA, De Windt LJ. Non-coding RNA in control of gene regulatory programs in cardiac development and disease. J Mol Cell Cardiol. 2015. doi: 10.1016/j.yjmcc.2015.03.014.   

2014

Nabben M, van Bree BW, Lenaers E, Hoeks J, Hesselink MK, Schaart G, Gijbels MJ, Glatz JF, da Silva GJ, de Windt LJ, Tian R, Mike E, Skapura DG, Wehrens XH, Schrauwen P. Lack of UCP3 does not affect skeletal muscle mitochondrial function under lipid-challenged conditions, but leads to sudden cardiac death. Basic Res Cardiol. 2014;109(6):447. [IF= 5.9]   
da Costa Martins PA, Leptidis S, De Windt LJ. Nuclear calcium transients: Hermes Propylaios in the heart. Circulation. 2014;130(3):221-223. [IF= 15.2]   
Poels EM, Bitsch N, Slenter JM, Kooi ME, de Theije CC, de Windt LJ, van Empel VP, da Costa Martins PA. Supplementing exposure to hypoxia with a copper depleted diet does not exacerbate right ventricular remodeling in mice. PLOS One. 2014;9(4):e92983. [IF= 3.7]   
Roncarati R, Anselmi CV, Losi MA, Papa L, Cavarretta E, Costa Martins PD, Jotti GS, Franzone A, Galastri L, Latronico MV, Imbriaco M, Esposito G, De Windt L, Betocchi S, Condorelli G. Circulating miR-29a, Among Other Upregulated microRNAs, is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients with Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2014;63(9):920-927. [IF= 14.7]   
Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knoll R, Leite-Moreira AF, Lourenco AP, Mayr M, Thum T, Tocchetti CG. Targeting myocardial remodelling to develop novel therapies for heart failure: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014;16(5):494-508. [IF= 6.6]   
Leite-Moreira AF, Lourenco AP, Balligand JL, Bauersachs J, Clerk A, De Windt LJ, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Kaminski KA, Knoll R, Mayr M, Tarone G, Thum T, Tocchetti CG. ESC Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. Eur J Heart Fail. 2014;16(5):509-518. [IF= 6.6]   

2013

De Windt LJ, Doevendans PA. Towards modern genetics, diagnostics and therapeutics of heart failure in a new era. BBA-Mol Basis Dis. 2013;1832:2401-2402. [IF= 5.4]   
Halkein J, De Windt LJ. miR-223: sailing to terra incognita for microRNAs in platelets. Thromb Haemostasis. 2013;110:1112-1113 [IF= 5.0]   
Kinet V, Halkein J, Dirkx E, De Windt LJ. Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet. 2013;4:214.   
Dirkx E, Gladka MM, Philippen LE, Armand AS, Kinet V, Leptidis S, El Azzouzi H, Salic K, Bourajjaj M, da Silva GJ, Olieslagers S, van der Nagel R, de Weger R, Bitsch N, Kisters N, Seyen S, Morikawa Y, Chanoine C, Heymans S, Volders PG, Thum T, Dimmeler S, Cserjesi P, Eschenhagen T, da Costa Martins PA, De Windt LJ. Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol. 2013;15:1282-1293. [IF= 19.5]   
Dirkx E, da Costa Martins PA, De Windt LJ. Regulation of fetal gene expression in heart failure. BBA-Mol Basis Dis. 2013;1832:2414-2424. [IF= 5.4]   
Lok SI, van Mil A, Bovenschen N, van der Weide P, van Kuik J, van Wichen D, Peeters T, Siera E, Winkens B, Sluijter JP, Doevendans PA, da Costa Martins PA, de Jonge N, de Weger RA Post-transcriptional Regulation of α-1-Antichymotrypsin by MicroRNA-137 in Chronic Heart Failure and Mechanical Support. Circ Heart Fail. 2013 Jul;6(4):853-861.l [IF= 6.6]   
Kuster DW, Mulders J, Ten Cate FJ, Michels M, Dos Remedios CG, da Costa Martins PA, van der Velden J, Oudejans CB. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. J Mol Cell Cardiol. 2013;65:59-66 [IF= 5.2].   
El Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, McClellan EA, Poels E, Sluimer JC, van den Hoogenhof MM, Armand AS, Yin X, Langley S, Bourajjaj M, Olieslagers S, Krishnan J, Vooijs M, Kurihara H, Stubbs A, Pinto YM, Krek W, Mayr M, da Costa Martins PA, Schrauwen P, De Windt LJ. The Hypoxia-Inducible MicroRNA Cluster miR-199a∼214 Targets Myocardial PPARδ and Impairs Mitochondrial Fatty Acid Oxidation. Cell Metab. 2013;18(3):341-354. [IF=17.55]   
Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, St�ger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Sch�rmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, De Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B. Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation. 2013 ;128(13):1420-1432. [IF= 15.2]   
Hirsch E, Hilfiker-Kleiner D, Balligand JL, Tarone G, De Windt L, Bauersachs J, Ferdinandy P, Davidson S, Hausenloy DJ, Schulz R. Interaction of the heart and its close and distant neighbours: report of the Meeting of the ESC Working Groups Myocardial Function and Cellular Biology. Cardiovasc Res. 2013;99(4):595-599. [IF = 5.9]   
Citro R, d'Avenia M, De Marco M, Giudice R, Mirra M, Ravera A, Silverio A, Farina R, Silvestri F, Gravina P, Villa F, Puca AA, De Windt L, De Laurenzi V, Bossone E, Turco MC, Piscione F. Polymorphisms of the antiapoptotic protein bag3 may play a role in the pathogenesis of tako-tsubo cardiomyopathy. Int J Cardiol. 2013;168(2):1663-1665. [IF=5.5]   
Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, De Windt LJ, da Costa Martins P. A Deep Sequencing Approach to Uncover the miRNOME in the Human Heart. PLoS One. 2013;8(2):e57800 [IF= 4.4]   
Tritsch E, Mallat Y, Lefebvre F, Diguet N, Escoubet B, Blanc J, De Windt LJ, Catalucci D, Vandecasteele G, Li Z, Mericskay M. : An SRF/miR-1 axis regulates NCX1 and Annexin A5 protein levels in the normal and failing heart. Cardiovasc Res. 2013;98:372-380. [IF= 6.1]   

2012

van Empel VP, De Windt LJ, da Costa Martins PA. Circulating miRNAs: reflecting or affecting cardiovascular disease? Curr Hypertens Rep. 2012;14(6):498-509. I [IF= 2.5] I   
Da Costa Martins PA, De Windt LJ. Targeting MicroRNA targets. Circ Res. 2012;111:506-508. I [IF= 9.5] I   
Bourgonje VJA, Schoenmakers M, Beekman JDM, van der Nagel R, Houtman MJC, Miedema LF, Antoons G, Sipido K, de Windt LJ, van Veen TAB, Vos MA. Relevance of Calmodulin/CaMKII Activation for Arrhythmogenesis in the AV-Block Dog. Heart Rhythm. 2012;9(11):1875-1883. I [IF= 4.1] I   
el Azzouzi H, Leptidis S, Bourajjaj M, van Bilsen M, da Costa Martins PA, De Windt LJ. MEK1 inhibits cardiac PPARa activity by direct interaction and prevents its nuclear localization. Plos One. 2012;7(6):e36799. I [IF= 4.4] I   
Da Costa Martins PA, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res. 2012;93:563-572. I [IF= 6.1] I   
Gladka MM, Da Costa Martins PA, De Windt LJ. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol. 2012;52:74-82. I [IF= 5.5] I   
Heijman J, Sp?§tjens RL, Seyen SR, Lentink V, Kuijpers HJ, Boulet IR, de Windt LJ, David M, Volders PG. Dominant-Negative Control of cAMP-Dependent IKs Upregulation in Human Long-QT Syndrome Type 1. Circ Res. 2012;110:211-219. I [IF= 9.5] I   
Kinet V, Dirkx E, De Windt LJ. Quaero muneris: Exploring microRNA function in cardiovascular disease. J Mol Cell Cardiol. 2012;51:1-2. I [IF= 5.5] I   

2011

Armand AS, Laziz I, Djeghloul D, L?©colle S, Bertrand A, Biondi O, De Windt LJ, Chanoine C. Apoptosis-Inducing Factor regulates skeletal muscle progenitor cell number and self-renewal. Plos One. 2011;6(11):e27283. I [IF= 4.4] I   
Bartelds B, Borgdorff MA, Smit-van Oosten A, Takens J, Boersma B, Nederhoff MG, Elzenga NJ, van Gilst WH, de Windt LJ, Berger RM. Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. Eur J Heart Fail. 2011;13:1275-1282. I [IF= 4.5] I   
Da Costa Martins PA, De Windt LJ. Letter concerning: 'Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo'. Cardiovasc Res. 2011;91:742-743. I [IF= 6.1] I   

2010

da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto amplification loop promoting calcineurin/NFAT signaling. Nature Cell Biol. 2010;12(12):1220-1227. I IF= 19.6 I   
den Hengst WA, Gielis JF, Lin JY, Van Schil PE, De Windt LJ, Moens AL. Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol. 2010;229;H1283-1299. I IF= 3.6 I   
Leenders JJ, Wijnen WJ, Hiller M, van der Made I, Lentink V, van Leeuwen RE, Herias V, Pokharel S, Heymans S, de Windt LJ, Hoydal MA, Pinto YM, Creemers EE. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem. 2010;285:27449-27456. I IF= 5.5 I   
da Costa Martins PA, De Windt LJ. miR-21: a miRaculous Socratic paradox. Cardiovasc Res. 2010;87(3):397-400. I IF= 6.1 I   
da Costa Martins PA, Leptidis S, Salic K, De Windt LJ. microRNA regulation in cardiovascular disease. Curr Drug Targets. 2010;11(8):900-906. I IF= 4.2 I   
Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035-1039. I IF= 10.0 I   
van Oort RJ, Respress JL, Sarma S, Reynolds C, Skapura DG, De Windt LJ, Wehrens XHT. Accelerated development of pressure overload-induced cardiac hypertrophy in a RyR2-R176Q knockin mouse model. Hypertension. 2010;55:932-938. I IF= 7.4 I   
el Azzouzi H, van Oort RJ, van der Nagel R, Bergmann MW, De Windt LJ. MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload. Eur J Heart Fail. 2010;12:4-12. I IF= 3.4 I   
van Rooij E, Fielitz J, Sutherland LB, Thijssen VL, Crijns HJ, Dimaio MJ, Shelton J, De Windt LJ, Hill JA, Olson EN. MEF2 and class II HDACs control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res. 2010;106:155-165. I IF= 10.0 I   

2009

El Azzouzi H, Bourajjaj M, da Costa Martins PA, De Windt LJ. Apoptosis in Cardiovascular Pathogenesis. In: Essentials of Apoptosis: A Guide for basic and Clinical Research, 2nd Edition. Eds. X-M Ying, Z Dong. Humana Press, UK: 2009, XXIII, 707, 505-522. I   
Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L, Bergmann MW. NF-kB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res. 2009 In Press I IF=6.1 I   
Gladka M, el azzouzi H, De Windt LJ, da Costa Martins PA. Aquaporin 7: the glycerol aquaeductus in the heart. Cardiovasc Res. 2009;83:3-4. I IF=6.1 I   

2008

Zelaray?°n L, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, van der Nagel R, Dietz R, De Windt LJ, Balligand JL, Bergmann MW. b-catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci USA. 105(50):19762-19767 I IF=9.6 I   
da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, Molkentin JD, De Windt LJ. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation. 2008;118:1567-1576 I IF=12.8 I Editorial   
Armand AS, Bourajjaj M, Martinez-Martinez S, da Costa Martins PA, Hatzis P, Seidler T, Redondo JM, De Windt LJ. Cooperative synergy between NFAT and MyoD regulates myogenin expression and myogenesis. J Biol Chem. 2008;283:29004-29010 I IF=5.6 I   
Bierhuizen MFA, Boulaksil M, van Stuijvenberg L, van der Nagel R, Jansen AT, Mutsaers NAM, Yildirim C, van Veen TAB, De Windt LJ, Vos MA, van Rijen HVM. In calcineurin-induced cardiac hypertrophy the expression of Nav1.5, Cx40 and Cx43 is reduced by different mechanisms. J Mol Cell Cardiol. 2008;45:373-384 I IF=4.9 I   
Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XT, De Windt LJ. NFATc2 is required in calcineurin-mediated cardiac hypertrophy and heart failure. J Biol Chem. 2008;283:22295-22303. I IF=5.6 I   
el Azouzzi H, De Windt LJ. Heart spotting. Basic Res Cardiol 2008;103:228-231. I IF=3.8 I   
Karatas A, Hegner B, De Windt LJ, Luft FC, Schubert C, Gross V, Akashi YJ, Gurgen D, Kintscher U, da Costa Goncalves AC, Regitz-Zagrosek V, Dragun D. Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension 2008;51:1-7. I IF=7.3 I   
da Costa Martins PA, De Windt LJ. Nix: the cardiac Styx between survival and death. Circulation 2008;177(3):338-340. I IF=12.8 I   

2007

Theunissen BEJ, Smeets PJH, Willemsen PH, De Windt LJ, Van Der Vusse GJ, Van Bilsen M. Activation of PPAR-delta inhibitis cardiac fibroblast proliferation and the differentiation to myofibroblasts. Cardiovasc Res. 2007; 75(3):519-29. I IF=6.1 I   
Bergmann MW, De Windt LJ. Linking cardiac mechanosensing at the sarcomere M-band, NF-κB signaling and cardiac hypertrophy. Hypertension 2007;49(6):1225-1227. I IF=7.3 I   
Fielitz J, van Rooij E, Spencer JA, Shelton JM, Latif S, van der Nagel R, Bezprozvannaya S, De Windt LJ, Richardson JA, Bassel-Duby R, Olson EN. Requirement of MuRF3 for maintanance of cardiac integrity following myocardial infarction. Proc Natl Acad Sci USA 2007;104:4377-4382. I IF=9.6 I   
Naseem RH, Meeson AP, Dimaio JM, White MD, Kallhoff JB, Humphries CG, Goetsch SC, De Windt LJ, Williams MA, Garry MG, Garry DJ. Reparative myocardial mechanisms in adult C57BL/6 and MRL mice following injury. Physiol Genomics. 2007;30(1):44-52. I IF=3.5 I   
Meijs MF, De Windt LJ, de Jonge N, Cramer MJ, Bots ML, Mali WP, Doevendans PA. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem. 2007;14(2):157-171. I IF=4.9 I   

2006

van Oort RJ, van Rooij E, Bourajjaj M, Schimmel J, Jansen MA, van der Nagel R, Doevendans PA, Schneider MD, van Echteld CJ, De Windt LJ. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation. 2006;114(4):298-308. I IF=12.8 I   
van Empel VP, Bertrand AT, van Oort RJ, van der Nagel R, Engelen M, van Rijen HV, Doevendans PA, Crijns HJ, Ackerman SL, Sluiter W, De Windt LJ. EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant. J Am Coll Cardiol. 2006;48(4):824-832. I IF=11.1 I   
Sanna B, Brandt EB, Kaiser RA, Pfluger P, Witt SA, Kimball TR, van Rooij E, De Windt LJ, Rothenberg ME, Tschop MH, Benoit SC, Molkentin JD. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A. 2006;103(19):7327-7332. I IF=9.6 I   
de Jonge N, Goumans MJ, Lips D, Hassink R, Vlug EJ, van der Meel R, Emmerson CD, Nijman J, De Windt L, Doevendans PA. Controlling cardiomyocyte survival. Novartis Found Symp. 2006;274:41-51. I   

2005

Wehrens XH, Lehnart SE, Reiken S, van der Nagel R, Morales R, Sun J, Cheng Z, Deng SX, De Windt LJ, Landry DW, Marks AR. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci U S A. 2005;102(27):9607-9612. I IF=9.6 I   
van Oort RJ, De Windt LJ. TOLL-erating cardiac hypertrophy following pressure overload. Cardiovasc Res. 2005;68(2):178-179. I IF=6.1 I   
van Empel VP, Bertrand AT, van der Nagel R, Kostin S, Doevendans PA, Crijns HJ, de Wit E, Sluiter W, Ackerman SL, De Windt LJ. Downregulation of apoptosis-inducing factor in harlequin mutant mice sensitizes the myocardium to oxidative stress-related cell death and pressure overload-induced decompensation. Circ Res. 2005;96(12):e92-e101. I IF=9.7 I   
van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67(1):21-29. I IF=6.1 I   
Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, De Windt LJ, Ludosky MA, Paulin D, Daegelen D, Tuil D, Li Z. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation. 2005;112(19):2930-2939. I IF=12.8 I   
Oh M, Rybkin, II, Copeland V, Czubryt MP, Shelton JM, van Rooij E, Richardson JA, Hill JA, De Windt LJ, Bassel-Duby R, Olson EN, Rothermel BA. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Mol Cell Biol. 2005;25(15):6629-6638. I IF=6.4 I   
Kilic A, Velic A, De Windt LJ, Fabritz L, Voss M, Mitko D, Zwiener M, Baba HA, van Eickels M, Schlatter E, Kuhn M. Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation. 2005;112(15):2307-2317. I IF=12.8 I   
Donners MM, Bot I, De Windt LJ, van Berkel TJ, Daemen MJ, Biessen EA, Heeneman S. Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. Am J Transplant. 2005;5(6):1204-1215. I IF=6.4 I   
Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, Godecke A, Baba HA, Kuhn M. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005;280(22):21594-21599. I IF=5.6 I   

2004

Van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63(3):487-499. I IF=6.1 I   
Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohe C, van Bilsen M, Doevendans PA. 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation. 2004;109(2):269-276. I IF=12.8 I   
van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004;94(3):e18-26. I IF=9.7 I   
Lips DJ, van der Nagel T, Steendijk P, Palmen M, Janssen BJ, van Dantzig JM, De Windt LJ, Doevendans PA. Left ventricular pressure-volume measurements in mice: comparison of closed-chest versus open-chest approach. Basic Res Cardiol. 2004;99(5):351-359. I IF=3.8 I   
Palmen M, Daemen MJ, De Windt LJ, Willems J, Dassen WR, Heeneman S, Zimmermann R, Van Bilsen M, Doevendans PA. Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J Am Coll Cardiol. 2004;44(5):1113-1123. I IF=11.1 I   
Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J, Pages G, De Windt LJ, Doevendans PA, Molkentin JD. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16):1938-1941. I IF=12.8 I   
Armand AS, De Windt LJ. Calcium cycling in heart failure: how the fast became too furious. Cardiovasc Res. 2004;62(3):439-441. I IF=6.1 I